Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.
- Non-binding term sheet signed with Sumitomo and Nakashima for Japan market entry
- Qcide® is a 100% natural insecticide derived from Australian Eucalyptus
- Targeting Japan’s $1 billion household nuisance insect pest market
- Definitive agreements expected by late April or early May 2026
- Sumitomo to manage logistics; Nakashima to handle formulation and retail supply
Bio-Gene’s Strategic Entry into Japan
Bio-Gene Technology Limited, an Australian bio-insecticide innovator, has taken a significant step towards expanding its footprint in Asia by partnering with two major Japanese companies, Sumitomo Corporation and Nakashima Trading Co. The collaboration aims to develop and market a range of insecticide products containing Bio-Gene’s flagship natural active ingredient, Qcide®, targeting Japan’s household nuisance insect pest market.
Japan’s home insecticide market is sizeable, estimated at around US$1 billion annually, with synthetic insecticides currently dominating. However, consumer preferences are shifting towards safer, eco-friendly, and natural products, creating a timely opportunity for Bio-Gene’s Qcide®, which is 100% natural and OMRI-listed, signifying its suitability for organic use.
The Partnership and Product Development
The agreement, currently a non-binding term sheet, outlines that Bio-Gene will produce Qcide oil from its Queensland Eucalyptus plantations and supply it to Nakashima via Sumitomo. Sumitomo will coordinate ordering, trade financing, transportation, and import approvals, leveraging its extensive global trading network. Nakashima, a well-established manufacturer and wholesaler in Japan, will focus on formulation, packaging, promotion, and distribution through multiple retail channels including home improvement centres, pharmacies, supermarkets, and e-commerce platforms.
Both Japanese partners bring complementary strengths: Sumitomo’s global logistics and financial expertise and Nakashima’s deep market knowledge and retail presence. This synergy is expected to accelerate Qcide’s market introduction, with a planned product launch in late 2026. Definitive binding agreements are anticipated by late April or early May 2026.
Market Context and Consumer Trends
Household nuisance insect pests in Japan include ants, cockroaches, flies, and termites, among others. Products targeting these pests are regulated differently from agricultural or public health insecticides, allowing for a faster route to market when claims are limited to nuisance control. The market is evolving, with consumers increasingly favouring insecticides that are low in toxicity, environmentally friendly, and convenient to use.
Qcide’s natural provenance, derived from steam-distilled Eucalyptus cloeziana biomass, aligns well with these consumer demands. Its approval by the Organic Materials Review Institute (OMRI) in the USA further enhances its credibility as a botanical pesticide, a key selling point in Japan’s growing natural insecticide segment.
Looking Ahead
Bio-Gene’s Managing Director Tim Grogan highlighted the strategic fit of Qcide in the Japanese market and the company’s focus on scaling production to meet anticipated demand. Meanwhile, Nakashima’s President Yoshiyuki Nakashima expressed enthusiasm about bringing a natural, effective product to Japanese households, noting the growing consumer interest in natural pest control solutions.
This partnership not only opens a new revenue stream for Bio-Gene but also positions the company at the forefront of a global shift towards sustainable pest management. The coming months will be critical as the parties finalize agreements and prepare for product launch, setting the stage for Bio-Gene’s broader international expansion.
Bottom Line?
Bio-Gene’s Japan launch could redefine natural pest control in a $1 billion market, with definitive deals due soon.
Questions in the middle?
- Will the definitive agreements signed in late April/early May include exclusivity or territorial rights?
- How will Bio-Gene scale its Queensland production to meet potential demand from Japan?
- What regulatory hurdles remain in Japan beyond import approval for Qcide-based products?